22944-67-8

Basic information

• Product Name: 1-BENZYL-1H-IMIDAZOL-2-YLAMINE
• Synonyms: 1-BENZYL-1H-IMIDAZOL-2-YLAMINE;2-AMINO-1-BENZYL-1H-IMIDAZOLE;2-AMINO-1-BENZYLIMIDAZOLE
• CAS NO: 22944-67-8
• Molecular Formula: C₁₀H₁₁N₃
• Molecular Weight: 173.21
• Product Categories: pharmacetical
• Mol File: 22944-67-8.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 386°C at 760 mmHg
• Flash Point: 187.2°C
• Appearance: /
• Density: 1.16g/cm³
• Vapor Pressure: 3.66E-06mmHg at 25°C
• Refractive Index: 1.622
• CAS DataBase Reference: 1-BENZYL-1H-IMIDAZOL-2-YLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BENZYL-1H-IMIDAZOL-2-YLAMINE(22944-67-8)
• EPA Substance Registry System: 1-BENZYL-1H-IMIDAZOL-2-YLAMINE(22944-67-8)

Safety Data

• Hazardous Substances Data: 22944-67-8(Hazardous Substances Data)

Usage

Synonyms

Benzylimidazole, 1-(2-imidazolyl)ethan-1-amine
These are alternative names for the compound, which can be used interchangeably.

Structure

Heterocyclic amine with a benzyl group and an imidazole ring
The compound is composed of a heterocyclic amine, which is a nitrogen-containing ring structure, with a benzyl group (C6H5-CH2-) attached to it and an imidazole ring.

Applications

Organic synthesis, pharmaceutical research
The compound is used as a building block or intermediate in the production of various pharmaceutical compounds.

Potential pharmacological properties

Antifungal, anti-inflammatory
Studies have shown that 1-Benzyl-1H-imidazol-2-ylamine may have potential as an antifungal and anti-inflammatory agent.

Importance

Research and development in medicinal chemistry
Due to its chemical properties and potential biological activities, the compound is considered an important molecule for research and development in the field of medicinal chemistry.

Solubility

Not specified in the provided material
The solubility of the compound in various solvents is not mentioned in the given information.

Stability

Not specified in the provided material
Information about the stability of the compound under different conditions is not provided in the material.

Reactivity

Not specified in the provided material
The reactivity of the compound with other substances or under specific conditions is not mentioned in the given information.

Safety precautions

Not specified in the provided material
Information about safety precautions or potential hazards associated with the compound is not provided in the material.

InChI:InChI=1/C10H11N3/c11-10-12-6-7-13(10)8-9-4-2-1-3-5-9/h1-7H,8H2,(H2,11,12)

Upstream product

• 501650-56-2 1-benzyl-2-nitro-1H-imidazole 
• 420-04-2 CYANAMID 
• 54879-88-8 N-benzyl-2,2-dimethoxyethylamine 
• 100-44-7 benzyl chloride 

Downstream Products

• 1028280-90-1 [(1-benzyl-1H-imidazol-2-ylamino)-(diethoxy-phosphoryl)-methyl]-phosphonic acid diethyl ester 
• 1332704-17-2 1-(1-benzyl-1H-imidazol-2-yl)-3-(3,4-dichlorophenyl)thiourea 
• 1404223-00-2 N-(1-tert-butyl-1H-imidazol-2-yl)-N'-(3,4-dichlorophenyl)guanidine hydrochloride 
• 1332703-98-6 N-(1-benzyl-1H-imidazol-2-yl)-N'-(3,4-dichlorophenyl)-N''-isopropylguanidine 
• 1332704-13-8 N-(1-benzyl-1H-imidazol-2-yl)-N'-(3,4-dichlorophenyl)-N''-isobutyrylguanidine 

Relevant articles and documents

Antimalarial activities of new guanidylimidazole and guanidylimidazoline derivatives

A series of new guanidylimidazole derivatives was prepared and evaluated in mice and Rhesus monkeys infected with malarial sporozoites. The majority of the new compounds showed poor metabolic stability and weak in vitro activities in three clones of Plasm

BENZAZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE AS AURORA KINASE INHIBITORS

The present invention relates to compounds and methods from the treatment of cancer. The invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising compounds that inhibit Aurora kinase, and methods for the treatment of cancer using the compounds of the presentation invention or pharmaceutical compositions comprising compounds of the present invention.